{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:09:03Z","timestamp":1787159343978,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ymgme.2025.109135","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T14:09:27Z","timestamp":1746713367000},"page":"109135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term enzyme replacement therapy: Findings from the mucopolysaccharidosis VI clinical surveillance program after 15\u00a0years follow-up"],"prefix":"10.1016","volume":"145","author":[{"given":"Barbara K.","family":"Burton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Harmatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Horvathova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Lail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Parini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Le\u00e3o","family":"Teles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2025.109135_bb0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2741\/4490","article-title":"Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment","volume":"21","author":"Harmatz","year":"2017","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ymgme.2025.109135_bb0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10545-011-9410-9","article-title":"Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP)","volume":"36","author":"Hendriksz","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109135_bb0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-5-5","article-title":"Mucopolysaccharidosis VI","volume":"5","author":"Valayannopoulos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109135_bb0020","doi-asserted-by":"crossref","first-page":"13456","DOI":"10.3390\/ijms222413456","article-title":"Mucopolysaccharidosis type VI, an updated overview of the disease","volume":"22","author":"D\u2019Avanzo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109135_bb0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1542\/peds.2006-2184","article-title":"Management guidelines for mucopolysaccharidosis VI","volume":"120","author":"Giugliani","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2025.109135_bb0030","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2174\/138920111795542688","article-title":"Recent advances in treatment approaches of mucopolysaccharidosis VI","volume":"12","author":"Giugliani","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ymgme.2025.109135_bb0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","article-title":"Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"94","author":"Harmatz","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109135_bb0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10545-009-9007-8","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase","volume":"33","author":"Harmatz","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109135_bb0045","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","article-title":"Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"144","author":"Harmatz","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109135_bb0050","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2025.109135_bb0055","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"Harmatz","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109135_bb0060","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/ajmg.a.36584","article-title":"Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)-10-year follow-up of patients who previously participated in an MPS VI survey study","volume":"164A","author":"Giugliani","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2025.109135_bb0065","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s13023-021-02060-4","article-title":"Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series","volume":"16","author":"Inci","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109135_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4238\/gmr.15017850","article-title":"Impact of early enzyme-replacement therapy for mucopolysaccharidosis VI: results of a long-term follow-up of Brazilian siblings","volume":"15","author":"Franco","year":"2016","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.ymgme.2025.109135_bb0075","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1399-0004.2009.01324.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age - a sibling control study","volume":"77","author":"McGill","year":"2010","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2025.109135_bb0080","first-page":"69","article-title":"Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-year follow up","volume":"13","author":"Furujo","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.ymgme.2025.109135_bb0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jimd.12028","article-title":"Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: systematic review","volume":"42","author":"Gomes","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109135_bb0090","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ymgme.2021.02.006","article-title":"Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: a resurvey study","volume":"133","author":"Horovitz","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109135_bb0095","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/jimd.12079","article-title":"Enzyme replacement therapy outcomes across the disease spectrum: findings from the mucopolysaccharidosis VI clinical surveillance program","volume":"42","author":"Harmatz","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109135_bb0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ymgme.2019.06.008","article-title":"Enzyme replacement therapy initiated in adulthood: findings from the mucopolysaccharidosis VI clinical surveillance program","volume":"127","author":"Lampe","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109135_bb0105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/PEP.0b013e3182095e44","article-title":"Reference values on the 6-minute walk test for children living in the United States","volume":"23","author":"Klepper","year":"2011","journal-title":"Pediatr. Phys. Ther."},{"key":"10.1016\/j.ymgme.2025.109135_bb0110","article-title":"Six minute walk distance and reference values in healthy Italian children: a cross-sectional study","volume":"13","author":"Vandoni","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.ymgme.2025.109135_bb0115","first-page":"1","article-title":"Growth charts for individuals with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"18","author":"Quartel","year":"2015","journal-title":"JIMD Rep"},{"key":"10.1016\/j.ymgme.2025.109135_bb0120","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-019-1080-y","article-title":"Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance","volume":"14","author":"Akyol","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109135_bb0125","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2022.08.007","article-title":"Findings from the Morquio a registry study (MARS) after 6 years: long-term outcomes of MPS IVA patients treated with elosulfase alfa","volume":"137","author":"Mitchell","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109135_bb0130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2021.03.006","article-title":"Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy","volume":"133","author":"Garcia","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"122","key":"10.1016\/j.ymgme.2025.109135_bb0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2017.03.008","article-title":"The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"2017","author":"Harmatz","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109135_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2466-13-49","article-title":"Reference values for the 6-minute walk test in healthy children and adolescents in Switzerland","volume":"13","author":"Ulrich","year":"2013","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.ymgme.2025.109135_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108507","article-title":"Causes of death in mucopolysaccharidoses","volume":"142","author":"Rintz","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109135_bb0150","first-page":"59","article-title":"Mortality in patients with Morquio syndrome a","volume":"15","author":"Lavery","year":"2015","journal-title":"JIMD Rep"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922500126X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922500126X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:45:44Z","timestamp":1762364744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671922500126X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S109671922500126X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109135","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term enzyme replacement therapy: Findings from the mucopolysaccharidosis VI clinical surveillance program after 15\u00a0years follow-up","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109135"}}